Metformin Ratiopharm

Metformin Hydrochloride, the active ingredient in Metformin Ratiopharm, is a biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes and may be prescribed for related insulin‑resistance conditions. GNH USA supplies Metformin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Ratiopharm is indicated for disorders of glucose metabolism and related endocrine conditions. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): reduces the risk of progression to type 2 diabetes. - Polycystic ovary syndrome: improves insulin sensitivity and may help restore ovulatory function.

Metformin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Metallic taste: transient alteration in taste perception. - Vitamin B12 deficiency: reduced absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals.

Metformin should be used with caution in specific clinical situations. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic disease: evaluate liver function as impaired metabolism may increase risk of lactic acidosis. - Alcohol intake: limit consumption to reduce lactic acidosis risk. - Cardiovascular status: monitor patients with unstable heart failure closely. - Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly needed. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance renal protective effects but require renal monitoring. - Beta‑blockers: can mask hypoglycaemia symptoms. - Corticosteroids: may increase blood glucose, necessitating dose adjustment.